Marker Therapeutics MRKR
NASDAQ MRKR
$0.99 -0.08 (-7.12%)
As of: Oct 23, 2026 · 2:32 PM EDT

Marker Therapeutics (MRKR) Amortization of Deferred Charges (2014)

Updated

Analysis

Marker Therapeutics (MRKR) Amortization of Deferred Charges (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,128.85 Bn 1,097.43 Bn 19.71 Bn
2 Johnson & Johnson 634.21 Bn 554.07 Bn 17.30 Bn
3 AbbVie 505.78 Bn 478.89 Bn 12.70 Bn
4 Merck 357.64 Bn 312.02 Bn 12.21 Bn
5 Novartis Ag 290.31 Bn 254.30 Bn 11.24 Bn
6 Astrazeneca 265.38 Bn 239.06 Bn 12.86 Bn
7 Amgen 238.11 Bn 193.51 Bn 7.24 Bn
8 Gilead Sciences 194.79 Bn 168.99 Bn 6.22 Bn
9 Pfizer 171.11 Bn 117.76 Bn 10.94 Bn
10 Marker Therapeutics 19.48 Mn -40.42 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2014 -483,636.00
API Access

Marker Therapeutics Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=MRKR&period=max&api_key=YOUR_API_KEY